The UK and US have forged a key bilateral deal that will ensure zero levies on British medicine products going into the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has committed to raise expenditure on drugs through the National Health Service (NHS). This pledge guarantees that tariffs on these crucial products will be held at nothing for a period of 36 months.
This deal follows previous threats to significantly raise tariffs on patented pharmaceutical products, with potential rates mentioned reaching 100%.
"This agreement with the UK strengthens the worldwide climate for innovative medicines and brings long-overdue balance to transatlantic pharmaceutical trade," a statement noted.
Commercial Impact
Drugs represent one of the the United Kingdom's largest goods shipped to the United States, which is by far the primary market for large British pharmaceutical firms.
Statistics indicate that in the year leading up to last September, the UK exported pharmaceutical products totaling over eleven billion pounds to the US. This amount represented 17.4% of total UK exports in that span.
"This deal protects work, increases capital expenditure and paves the way for the UK to establish itself as a global hub for medical research," a minister stated.
Detailed UK Commitments
The agreement involves several specific pledges from the UK:
- Higher Cost Ceiling: The UK will lift the price threshold at which it deems new treatments to be too expensive by a quarter.
- Increased NHS Spending: There is a goal to increase overall health service expenditure on medicines from 0.3 percent of the national economy to 0.6 percent over the next decade.
- Rebate Cap: The percentage pharmaceutical firms must return to the NHS to stay within budget will be limited at 15%. Previously, refunds exceeded twenty percent.
Recent Tensions
The pact comes amid a protracted row between the drug companies and the ministers over spending levels and regulatory access.
These tensions were heightened by arguments that US patients were paying a premium for the identical medicines than consumers in the other developed nations.
Over the last 18 months, several major drug company projects in the UK have been halted or abandoned, while multi-billion-dollar funding commitments have been pledged toward American operations.
A senior figure acknowledged that the NHS must invest a greater share on drugs, noting that its budget allocation on drugs had declined as a percentage of its total funding over the last ten years.